Effect of Oral N-Acetylcysteine Supplementation on the Immunity System in Patients with Acute Myocardial Infarction
Hartley A, Marshall DC, Salciccioli JD, et al. Trends in mortality from ischemic heart disease and cerebrovascular disease in Europe: 1980 to 2009. Circulation. 2016;133(20):1916–26.
Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics - 2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322.
Dharma S, Juzar DA, Firdaus I, et al. Acute myocardial infarction system of care in the third world. Neth Heart J. 2012;20(6):254–9.
Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci. 1982;389:39–48.
Tomoda H, Aoki N. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J. 2000;140:324–8.
Makrygiannis SS, Ampartzidou OS, Zairis MN, et al. Prognostic usefulness of serial C-reactive protein measurements in ST-elevation acute myocardial infarction. Am J Cardiol. 2013;111:26–30.
Carbone F. Pathophysiological role of neutrophils in acute myocardial infarction. Thromb Haemost. 2013; 110(3):501–14.
Arnhold J, Flemmig J. Human myeloperoxidase in innate and acquired immunity. Arch Biochem Biophys. 2010;500(1):92–106.
Khan A, Alsahli MA, Rahmani AH. Myeloperoxidase as an active disease biomarker: Recent biochemical and pathological perspectives. Med Sci. 2018;6(2):E33.
Liu FT, Yang R, Hsu DK. Galectine in acute and chronic inflammation. Ann N Y Acad Sci. 2012; 1253:80–91.
Yu L. The role of galectin-3 in cardiac remodeling and fibrogenesis. Groningen: 2012. p. 152.
Radomska-Leśniewska DM, Skopiñski P. N-acetylcysteine as an anti-oxidant and anti-inflammatory drug and its some clinical applications. Centr Eur J Immunol. 2012;37(1):57-66.
Yesilbursa D, Serdar A, Senturk T, et al. Effect of N-acetylcysteine on oxidative stress and ventricular function in patients with myocardial infarction. Heart Vessels. 2006;21:33–7.
Teng N, Maghzal GJ, Thalib J, et al. The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture. Redox Rep. 2017;22(2):51–73.
Kilciksiz S, Demirel C, Erdal N, et al. The effect of N-acetylcystein on biomarkers for radiation-induced oxidative damage in a rat model. Acta Med Okayama. 2008;62(6);403–9.
Pasupathy S, Tavella R, Grover S, et al. Early use of N-acetylcysteine (NAC) with nitrate therapy in patients undergoing primary percutaneous coronary intervention for ST-Segment Elevation Myocardial Infarction Reduces Myocardial Infarct Size (the NACIAM trial). Circulation. 2017;136(10):894-903.
Yang RY, Rabinovich GA, Liu FT. Galectins: Structure, function and therapeutic potential. Expert Rev Mol Med. 2008;10:e17.
Sharma UC, Mosleh W, Chaudhari MR, et al. Myocardial and serum galectin-3 expression dynamics marks post-myocardial infarction cardiac remodeling. Heart Lug Circ. 2016;26(7):736–45.
Van der Velde AR, Lexis CPH, Meijers WC, et al. Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. Clin Chim Acta. 2016;452:50–7.
Talasaz AH, Khalili H, Jenab Y, et al. N-Acetylcysteine effects on transforming growth factor-β and tumor necrosis factor-a serum levels as pro-fibrotic and inflammatory biomarkers in patients following ST-segment elevation myocardial infarction. Drugs R D. 2013;13:199–205.
Talasaz AH, Khalili H, Fahimi F, et al. Effects of N-acetylcysteine on the cardiac remodeling biomarkers and major adverse events following acute myocardial infarction: A randomized clinical trial. Am J Cardiovasc Drugs. 2014;14:51–61.
Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–77.
- There are currently no refbacks.